Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* 18 years of age or older, male or female~* Receiving a stable opioid regimen~* Documented opioid-induced constipation~* Willingness to stop all laxatives and other bowel regimens. The use of constipation rescue medication will be allowed during the study.~Main Exclusion Criteria:~* Life expectancy less than 6 months~* Active substance abuse~* Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other active medical disorders associated with diarrhea or intermittent loose stools or constipation~* Pregnant or breast-feeding~* Any receipt of an investigational medication within 30 days of screening~* History or presence of specific cardiac, neurologic, endocrine and/or psychiatric conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): Placebo
- B (Type: EXPERIMENTAL): NKTR-118

Based on this trial design, predict the completion outcome and termination type (if applicable).